National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting, 71627 [2013-28559]
Download as PDF
<![CDATA[
sroberts on DSK5SPTVN1PROD with NOTICES
Federal Register / Vol. 78, No. 230 / Friday, November 29, 2013 / Notices
Methods of Modulating
Chemotherapeutic Cytotoxicity
Description of Technology:
Investigators at the National Cancer
Institute (NCI) have discovered that
blockade of the signalling activity of a
single cell-surface receptor, CD47, in
cancer cells results in enhanced
sensitivity of cancer cells to
chemotherapy treatment and in healthy
tissues reduces damage to normal cells.
Many chemotherapeutic agents cause
significant cytotoxicity to non-cancer
(‘‘normal’’) cells, resulting in
undesirable side-effects and often
limiting the dose and/or duration of
chemotherapy that can be administered
to a patient. The present invention
relates to a method of using CD47modulating compounds in combination
with a chemotherapeutic agent to
increase the efficacy of that agent
against inhibiting tumor growth. The
invention also relates to methods for
preventing damage to heart tissue
associated with the use of anthracycline
chemotherapy. The current invention
builds on the NIH’s previous discoveries
of antibodies, antisense morpholino
oligonucleotides, and peptide
compounds that modulate CD47.
Potential Commercial Applications:
Combination Chemotherapy
Competitive Advantages:
• Enhance effectiveness of
chemotherapeutic agents.
• Limit off target effects on normal
tissue.
• Reduces cytotoxicity of normal
cells.
• Provides cardioprotection for
anthracyclines.
Development Stage:
• Early-stage.
• Pre-clinical.
• In vitro data available.
• In vivo data available (animal).
Inventors: David D. Roberts and David
R. Soto Pantoja (NCI).
Publication: Soto-Pantoja DR, et al.
CD47 deficiency confers cell and tissue
radioprotection by activation of
autophagy. Autophagy. 2012
Nov;8(11):1628–42. [PMID 22874555]
Intellectual Property: HHS Reference
No. E–296–2011/0—US Application No.
61/779,587 filed 13 March 2013
Related Technology: HHS Reference
No. E–227–2006/5–
• US Application No. 12/444,364
filed 03 April 2009.
• CA Application No. 2,665,287 filed
05 October 2007.
• EP Application No. 07868382.8
filed 27 March 2009.
• US Application No. 13/546,941
filed 11 July 2012.
• US Application No. 13/546,931
filed 11 July 2012.
VerDate Mar<15>2010
17:56 Nov 27, 2013
Jkt 232001
Licensing Contact: Charlene Maddox,
Ph.D.; 301–435–4689;
sydnorc@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute,
Laboratory of Pathology, is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate or
commercialize CD47 targeting
therapeutics, cardioprotection,
autophagy modulation. For
collaboration opportunities, please
contact John D. Hewes, Ph.D. at
hewesj@mail.nih.gov.
Dated: November 21, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2013–28558 Filed 11–27–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Biomedical Imaging and Bioengineering
Special Emphasis Panel; NIBIB 2014–05
Reducing Health Disparity SBIR Review.
Date: March 6, 2014.
Time: 10:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, Suite 920, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Ruixia Zhou, Ph.D.,
Scientific Review Officer, 6707 Democracy
Boulevard, Suite 957, Bethesda, MD 20892,
301–496–4773, zhour@mail.nih.gov.
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
71627
Dated: November 22, 2013.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–28559 Filed 11–27–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; K22 Grant
Applications for PAR–12–121.
Date: December 3, 2013.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W030, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Sergei Radaev, Ph.D.,
Scientific Review Officer, Resources and
Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W634, Bethesda, MD 20892, 240–
276–6466, sradaev@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting date due to
scheduling conflicts.
Information is also available on the
Institute’s/Center’s home page: https://
deainfo.nci.nih.gov/advisory/sep/sep.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS).
E:\FR\FM\29NON1.SGM
29NON1
]]>Agencies
[Federal Register Volume 78, Number 230 (Friday, November 29, 2013)]
[Notices]
[Page 71627]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-28559]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical Imaging and Bioengineering;
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Biomedical Imaging and
Bioengineering Special Emphasis Panel; NIBIB 2014-05 Reducing Health
Disparity SBIR Review.
Date: March 6, 2014.
Time: 10:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, Suite
920, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Ruixia Zhou, Ph.D., Scientific Review Officer,
6707 Democracy Boulevard, Suite 957, Bethesda, MD 20892, 301-496-
4773, zhour@mail.nih.gov.
Dated: November 22, 2013.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2013-28559 Filed 11-27-13; 8:45 am]
BILLING CODE 4140-01-P
